Market News AIOpen the app

LCTX stock news · Lineage Cell Therapeutics, Inc.

Stories about Lineage Cell Therapeutics, Inc. (LCTX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for LCTX

Follow Lineage Cell Therapeutics, Inc. (LCTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LCTX
Free on the App Store and Google Play, or on the web.
  1. Nov 12, 2026, 4:21 PM ET · Market

    Lineage Cell Therapeutics is buying NeuroAirmid Therapeutics to boost its work on a treatment for Huntington's Disease.

    Neutral

    Lineage acquired NeuroAirmid for $2.4 million cash and 2.2 million shares, plus up to $48 million in milestone payments. Its promise is balanced by costs and unproven results.

  2. Oct 12, 2026, 7:52 AM ET · Results

    Lineage Cell Therapeutics shared details from its Q2 2026 earnings call, showing $50.8 million in cash.

    Neutral

    Lineage said its cash could fund operations into Q3 2028 and described advancing cell programs. Lower revenue and income tied to a non-cash gain leave the company’s outlook unchanged.